

Oncology Testing for BCR-ABL Fusion Gene

Background:

The Philadelphia chromosome (Ph), a derivative chromosome 22 resulting from a translocation between chromosomes 9 and 22 causing the *BCR-ABL* fusion, is present in approximately 95% of chronic myeloid leukemia (CML) and 25-30% of adult acute lymphoblastic leukemia (ALL) cases. This fusion is also seen in 2-4% of children with ALL. Chronic neutrophilic leukemia (CNL) is also associated with the Philadelphia chromosome and a specific *BCR-ABL* transcript. In general, the ratio of the fusion to a reference control can be used for diagnosis, prognosis, and ongoing therapeutic monitoring.

The *BCR-ABL* rearrangement results in the generation of fusion protein with constitutive tyrosine kinase activity. Based on the specific breakpoints of the rearrangement, several different isoforms of the *BCR-ABL* fusion protein can be generated, which correlate with different leukemic phenotypes. According to recommendations from the National Comprehensive Cancer Network, “identification of specific recurrent genetic abnormalities is critical for disease evaluation, optimal risk stratification and treatment planning” (NCCN Guidelines Version 2.2012, “Acute Lymphoblastic Leukemia”).

In approximately 95% of CML cases, the major rearrangement is present and the p210 fusion protein is produced. In most children with Ph+ ALL, the minor rearrangement generates the p190 fusion protein. Adults with Ph+ ALL may have either the p190 or the p210 transcript. CNL is characterized by the p230 isoform and has a significantly different clinical course than CML or ALL, which further demonstrates the importance of distinguishing the different isoforms.

For CML patients, associations have been established between *BCR-ABL/ABL* international scale (IS) values and assessment of treatment milestones and therapeutic

efficacy. For the p210 fusion transcript, *BCR-ABL/ABL* IS values indicating a major molecular response (MMR) correlate with excellent progression-free survival. For patients who are suspected to have emerging drug resistance or who fail to achieve a MMR initially, evaluation of *ABL* kinase domain mutations may identify the cause of resistance and potentially guide treatment changes.

For Ph+ ALL patients, associations for p190 IS values have not been established. For the p190 fusion transcript, an increasing *BCR-ABL/ABL* ratio may indicate a poor initial response in Ph+ ALL patients. Evaluation of *ABL* kinase domain mutations in recurrent Ph+ ALL can help guide changes in therapy.

Available Tests from Cincinnati Children’s Diagnostic Laboratories:

***BCR-ABL* FISH cytogenetic testing** detects the presence of the 9;22 translocation and the *BCR-ABL* fusion gene within somatic cells. This test may also identify an additional copy of Ph in cells or an atypical 9/22 translocation. FISH cytogenetic testing is indicated as an initial evaluation for patients suspected to have CML or ALL and then for monitoring disease status, however, it does not differentiate between the different isoforms (p190, p210, and p230).

Qualitative *BCR-ABL* testing is indicated as an initial evaluation for patients known to have a positive FISH cytogenetic test for *BCR-ABL*. The qualitative *BCR-ABL* test can determine the specific type (isoform) of the Philadelphia chromosome present which is important for appropriate diagnosis and treatment. Our qualitative *BCR-ABL* test detects the presence of the p190, p210 and p230 isoforms; however, the qualitative test does not measure the levels of the transcripts.

Quantitative *BCR-ABL* testing is indicated for monitoring of disease for any patient positive for the p210 or p190 *BCR-ABL* fusion gene by qualitative assay. Our laboratory uses a methodology that measures the number of copies of the p210 or p190 *BCR-ABL* fusion gene present relative to the number of *ABL* gene transcripts in the same sample. Comparing the ratio of disease fusion gene copies to normal gene copies allows physicians to have a numerical measure of response to therapy and allows for a more sensitive monitoring for possible disease relapse.

p210 isoform International Scale A major molecular response is considered to be a 3-log reduction in the ratio from baseline of diagnosis (for example, 100% *BCR-ABL/ABL* ratio must reduce to 0.1% *BCR-ABL/ABL* ratio or 10 copies of fusion gene compared to 10,000 copies of the *ABL* gene). To facilitate comparison of quantitative RT-PCR results for the p210 *BCR-ABL* fusion gene between laboratories and platforms, International Scale (IS) reference materials were established by the World Health Organization and results of this assay are reported on the IS.

IS reference materials have not been established for the p190 *BCR-ABL* fusion gene.

Testing Strategy:


Initial evaluation:

***BCR-ABL* FISH cytogenetic testing** is performed to detect the *BCR-ABL* fusion gene as well as to provide an estimate of the percentage of cells carrying the fusion gene. **Qualitative *BCR-ABL* testing** is then performed to determine which isoform is present. A baseline sample should then be sent for **quantitative *BCR-ABL* testing** for the isoform identified.

Monitoring of disease status:

Disease can be monitored by ***BCR-ABL* FISH cytogenetic testing** until the assay can no longer detect the fusion gene, and then a sample for **quantitative *BCR-ABL* testing** should be sent for continued monitoring of disease, if the patient has the p190 or p210 isoform of the *BCR-ABL* fusion gene.

Oncology Testing for *BCR-ABL* Fusion Gene: Testing Flow Chart



Testing Methodology:

***BCR-ABL* FISH cytogenetic testing:**

Fluorescence in situ hybridization with probes for the 9;22 translocation.

Qualitative *BCR-ABL* testing: RNA isolation with reverse transcription nested PCR and gel detection of PCR products.

Quantitative *BCR-ABL* testing: RNA isolation with RQ-PCR reaction to precisely quantitate the amount of control and fusion gene transcripts.

Sensitivity and Accuracy:

***BCR-ABL* FISH cytogenetic testing:** For initial analysis, 250 nuclei are counted. For disease monitoring, with a previously abnormal result, up to 500 nuclei may be counted.

Qualitative *BCR-ABL* testing: One cell with fusion transcripts per 10,000 normal cells.

Quantitative *BCR-ABL* (p210) testing: Sensitivity studies within the laboratory have shown that a ratio as low as 0.1% can be detected. Because of variability of the RNA quantity within a specimen and assay variability, only changes of 0.5 log or greater should be considered significant. Therefore results of 1% *BCR-ABL/ABL* would be considered equivalent to any results between 3% and 0.3%.

Quantitative *BCR-ABL* (p190) testing: Sensitivity studies within the laboratory have shown that a ratio as low as 0.02% can be detected. Because of variability of the RNA quantity within a specimen and assay variability, only changes of 0.5 log or greater should be considered significant. Therefore results of 1% *BCR-ABL/ABL* would be considered equivalent to any results between 3% and 0.3%.

Specimens:

***BCR-ABL* FISH cytogenetic testing:**

1-3 ml bone marrow OR peripheral blood in green (Na Hep) tube.

Qualitative *BCR-ABL* testing: 3 mls peripheral blood OR bone marrow in purple (EDTA) tube (Please note that samples must be received within 48 hours after collection).

Quantitative *BCR-ABL* testing: 5-10 mls peripheral blood OR 3-5 mls bone marrow in purple (EDTA) tube (Please note that samples must be received within 24 hours after collection).

Turn-Around Times:

***BCR-ABL* FISH cytogenetic testing:** 1 day.

Qualitative *BCR-ABL* testing: 6 business days.

Quantitative *BCR-ABL* testing: 10 days.

Costs:

Please call 1-866-450-4198 for pricing or with any billing questions.

CPT Codes:

***BCR-ABL* FISH cytogenetic testing:** 88271(x2), 88275 (add 88237 if cells need to be cultured)

Qualitative *BCR-ABL* (p190, p210, & p230) testing: 81206, 81207, 81208

Quantitative *BCR-ABL* (p210) testing: 81206

Quantitative *BCR-ABL* (p190) testing: 81207

Shipping Instructions:

Please enclose **test requisition** with sample.

All information must be completed before sample can be processed.

Place samples in styrofoam mailer and ship at room temperature by overnight Federal Express to arrive Monday through Friday.

Ship to:

Cytogenetics and Molecular Genetics Laboratories
3333 Burnet Avenue NRB 1042
Cincinnati, OH 45229
513-636-4474

References:

Baccarani M, et al. (2006). *Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet*. *Blood* 108:1809.

Beillard E, et al. (2003). *Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)- a European Against Cancer program*. *Leukemia* 17:2474.

Borowitz MJ, et al. (2008). *B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities*. In: Swerdlow SH, et al. eds. *WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues*. Lyon, France: IARC Press; 2008:171.

Gabert J, et al. (2003). *Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia- A Europe Against Cancer Program*. *Leukemia* 17:2318.

Hughes TP, et al. (2003). *Frequency of major molecular responses to imatinib or interferon a plus cytarabine in newly diagnosed chronic myeloid leukemia*. *Blood* 103:2873.

Hughes T, et al. (2006). *Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results*. *Blood* 108:28.

Jones D, Rajyalakshmi et al. (2008). *BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias*. *Blood* 112:5190.

Jones D, et al. (2008) *Kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors*. *Cancer* 113:985.

Jones, D, et al (2009) *Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology*. *J Mol Diagn*, 11(1), 4-11.

Kantarjian H, et al. (2008). *Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods*. *Blood* 111:1774.

Muller MC, et al. (2008). *Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories*. *Leukemia* 22:96.

NCCN Clinical Practice Guidelines in Oncology. (2012) *Acute Lymphoblastic Leukemia*. Version 2.2012.

Press et al., (2007). *A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response (CCR)*. *Clin Cancer Research* 13:6136.

Radojkovic M, et al. (2009) *Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis*. *Leukemia Research*, 33(6), e10-12.

Vardiman JW et al (2008). *Chronic myelogenous leukemia, BCR-ABL1 positive*. In: Swerdlow SH, et al. eds. *WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues*. Lyon, France: IARC Press; 2008:180.

White HE, et al (2010). *Establishment of the first World Health Organization International Genetic Reference Panel for quantification of BCR-ABL mRNA*. *Blood* 116:e111-7.